March 2011

CHIEF MEDICAL EDITOR'S PAGE: Carpe Diem

Steven D. Vold, MD, Chief Medical Editor

The Literature

KRISTY AHRLICH, MD

Clinician Scientist's Corner

Why Do I Perform Research?

ANJALI BHORADE, MD, MSCI

Research Results

The Zhongshan Angle Closure Prevention Trial

Given the large population at risk there, China is the ideal location for research on the efficacy and safety of laser peripheral iridotomy for the prevention of primary angle closure.

DAVID S. FRIEDMAN, MD, MPH, PHD

Word From the Cutting Edge

An overview of several of the presentations at this year's Innovative Glaucoma Surgery Symposium.

LEON W. HERNDON, MD

Highlights of the AGS Annual Meeting

The latest research findings from the 21st annual meeting of the American Glaucoma Society.

GEOFFREY T. EMERICK, MD

Landmark Studies

Learn to Ask Yourself the Essential Questions

RONALD L. FELLMAN, MD

Challenging Cases

Management of Angle Closure in the Nanophthalmic Patient

DEVESH K. VARMA, MD, FRCSC, AND IQBAL IKE K. AHMED, MD, FRCSC

Technology Today

Reconsidering the Gold Standard of Tonometry

A glaucoma specialist argues for a new method of applanation tonometry.

DAN L. EISENBERG, MD

Sidebar: Holding on to Goldmann Tonometry

Considerations before replacing the gold standard.

ADAM C. REYNOLDS, MD

The Ganglion Cell Complex

Spectral-domain optical coherence tomography allows measurements of macular thickness that may have a complementary role in glaucoma diagnosis.

AHMAD A. AREF, MD, AND DONALD L. BUDENZ, MD, MPH

Cover Stories

Is Glaucoma Screening Worthwhile?

Like the process itself, assessing its merits is complex.

RENATA PICCIANI, MD; RICHARD K. LEE, MD, PHD; AND JEFFREY D. HENDERER, MD

The Cost-effective Use of Diagnostic Technologies

An overview of frequently ordered tests and their cost-benefit utility.

JEFFREY A. KAMMER, MD

Maximizing the Benefits of Topical Therapy

Cost is a factor, but it does not trump efficacy, safety, or tolerability.

RONALD L. GROSS, MD, AND RYAN D. VINCENT, MD

Improving Patients' Adherence to Glaucoma Therapy

Patients can tell you a lot, if you let them.

GAIL F. SCHWARTZ, MD

The Role of Surgical Intervention in Reducing Costs

New treatments will increasingly require a health economic evaluation before regulatory authorities will allow their use. With improved clinical techniques and long-term outcomes, glaucoma surgery has the potential to be more cost-effective than other treatment modalities.

JONATHAN CLARKE, MD, FRCOPHTH; TRISHAL BOODHNA, MSC; AND PENG TEE KHAW, PHD, FRCS, FRCP, FRCOPHTH, FRCPATH, CBIOL FSB, FARVO, FMEDSCI

An Industry Perspective

The potential impact of emerging surgical technologies on glaucoma.

WILLIAM J. LINK, PHD

Optimizing Glaucoma Practice Models

William L. Rich III, MD, David G. Godfrey, MD, and Paul Lee, MD, JD

Therapeutics Update

Reducing the Preservative Load in Glaucoma Therapy

Improve the health of the ocular surface in patients taking IOP-lowering medications.

ROBERT D. FECHTNER, MD

Practice Pointers

Marketing Methodologies for High-Growth Practices

Tips for separating practices growing at 20% from those pacing the population.

TIMOTHY BUCKLEY, MBA, BSME

Inside Eyetube.net

Evolutions and Revolutions in Glaucoma Surgery

NATHAN M. RADCLIFFE, MD

INDUSTRY NEWS AND INNOVAT IONS

5 Questions with Louis R. Pasquale, MD

Dr. Pasquale discusses the three Rs: research, Red Sox, and running.